Filing Flows › Neogenomics (NEO) › Capital expenditures
Neogenomics (NEO) capital expenditures by quarter
Neogenomics' capital expenditures were $8.2M in Q2 2026 (second quarter 2026), +4% from Q4 2025. Over the last 4 quarters it ranged from $6.3M (Q2 2025) to $8.3M (Q3 2025).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $8.2M | +4% | +30% |
| Q4 2025 | $7.9M | -5% | — |
| Q3 2025 | $8.3M | +31% | — |
| Q2 2025 | $6.3M | — | — |
Q2 2026 at a glance
Neogenomics, Q2 2026: revenue $202M (+11% year over year), operating margin -4.8%, net earnings $2.2M, operating cash flow $20.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Neogenomics' capital expenditures?
Neogenomics' capital expenditures were $8.2M in Q2 2026 (second quarter 2026), +4% from Q4 2025.
How has Neogenomics' capital expenditures changed?
Over the last 4 quarters it ranged from $6.3M (Q2 2025) to $8.3M (Q3 2025).